The challenges of developing an antiviral agent for the treatment of smallpox using the animal efficacy rule

Author： Painter George Buller Mark Kern Earl Huggins John Moyer Richard Painter Wendy Doucette Marna Robertson Alice

ISSN： 1746-0794

Source： Future Virology, Vol.1, Iss.2, 2006-03, pp. : 173-179

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Debate over FDA drug approval using new `animal rule'

Inpharma, Vol. 1, Iss. 1379, 2003-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Development of the small-molecule antiviral ST-246^®® as a smallpox therapeutic

By Grosenbach Douglas W Jordan Robert Hruby Dennis E

Future Virology, Vol. 6, Iss. 5, 2011-05 ,pp. : 653-671

Future Medicine

Access to resources Recommend Favorite

Two Possibilities How to Increase the Efficacy of Antidotal Treatment of Nerve agent Poisonings

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 1, 2012-01 ,pp. : 24-34

Bentham Science Publishers

Access to resources Recommend Favorite

Antiviral Treatment of Cytomegalovirus Infection

Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol. 11, Iss. 5, 2011-10 ,pp. : 475-503

Bentham Science Publishers

Access to resources Recommend Favorite

Ribavirin - current status of a broad spectrum antiviral agent

By Snell Noel J C

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 8, 2001-08 ,pp. : 1317-1324

Informa Healthcare

Access to resources Recommend Favorite